🧵 Why "Cheap" is relative.
Most investors look for PEG < 1.0. In a premium market like 2026, you'll miss the best compounders waiting for a 1.0.
The Lynch Pin strategy uses historical PEG data to find valuation anomalies.
Here is the quant math behind the Pin: 👇
$MSFT
🤖: Microsoft (A+) is a software giant demonstrating strong EPS growth. PEG 1.13 (vs 1.87 mean) shows it's still undervalued given its quality. Base ROI 25.9% relies on continued strong execution & PE re-rating. A high-conviction "sleep well" compounder.
📊 Reverse 5Y DCF: Microsoft, a diversified technology leader in cloud, software, and gaming, benefits from deep ecosystem integration and recurring revenue. Its 25.9% base ROI requires EPS to compound at 17.1%/yr for 5 years while PE re-rates from current 19.3x to implied 32x. Operationally, this means maintaining strong revenue growth (+18%), managing COGS (+22%) which has risen, but leveraging R&D (+9%), S&M (+10%), G&A (+11%) efficiencies to deliver robust operating (+20%) and net income (+23%) expansion. Given its A+ income grade and consistent innovation, this path is highly achievable.
🐻 "Stomach Test" (why it can underperform in the next 5 years): Microsoft's key risks include intensified competition in cloud computing from AWS and Google, potential regulatory scrutiny over its market dominance, and the constant need to innovate in rapidly evolving tech sectors like AI. While COGS (+22%) has outpaced revenue growth, any further margin pressure could challenge the aggressive PE re-rating required. A significant economic slowdown could also impact enterprise spending.
$PLTR
🤖: Palantir is a high-octane growth monster. Revenue up 85% and profits up over 300% justify the hefty 54.2x Fwd PE. A solid sleep-well compounder if you can stomach the valuation volatility.
📊 Reverse 5Y DCF: Palantir provides mission-critical enterprise AI and defense data operating systems, enjoying unparalleled customer lock-in. The math: a 22.5% base ROI requires EPS to compound at 33.3%/yr for 5 years while PE re-rates from current 54.2x to implied 83x. Operationally, this means continuing to scale commercial revenues by 85% while keeping overhead growth in check. This is realistic given their incredible 307% net income scaling.
🐻 "Stomach Test" (why it can underperform in the next 5 years): Government contracts are notoriously lumpy and prone to sudden budget cuts. If commercial enterprise AI spend turns out to be a passing fad, Palantir's sky-high 54.2x Fwd PE will compress violently, limiting returns to its 12.4% bear scenario.
$PLTR
🤖: Palantir is a high-octane growth monster. Revenue up 85% and profits up over 300% justify the hefty 54.2x Fwd PE. A solid sleep-well compounder if you can stomach the valuation volatility.
📊 Reverse 5Y DCF: Palantir provides mission-critical enterprise AI and defense data operating systems, enjoying unparalleled customer lock-in. The math: a 22.5% base ROI requires EPS to compound at 33.3%/yr for 5 years while PE re-rates from current 54.2x to implied 83x. Operationally, this means continuing to scale commercial revenues by 85% while keeping overhead growth in check. This is realistic given their incredible 307% net income scaling.
🐻 "Stomach Test" (why it can underperform in the next 5 years): Government contracts are notoriously lumpy and prone to sudden budget cuts. If commercial enterprise AI spend turns out to be a passing fad, Palantir's sky-high 54.2x Fwd PE will compress violently, limiting returns to its 12.4% bear scenario.
$HUBS
🤖: HubSpot is an elite compounder at a fire-sale price of 11.9x Fwd PE. With an A+ grade, 41% growth, and a 0.29 PEG, the market has completely mispriced this operational juggernaut.
📊 Reverse 5Y DCF: HubSpot provides marketing and sales CRM platforms for mid-market businesses, building a strong platform ecosystem moat. The math: a 42.5% base ROI requires EPS to compound at 41.0%/yr for 5 years while PE re-rates from current 11.9x to implied 102x. Operationally, this means sustaining 23% revenue growth while maintaining their highly efficient 210% operating income expansion. This is highly realistic and looks incredibly cheap at current prices.
🐻 "Stomach Test" (why it can underperform in the next 5 years): HubSpot sells primarily to small and medium businesses, which are the first to fail in a recession. A sharp economic downturn would cause churn to spike and growth to plummet below the 41.0% target, dragging returns down to the -7.4% bear projection.
$HUBS
🤖: HubSpot is an elite compounder at a fire-sale price of 11.9x Fwd PE. With an A+ grade, 41% growth, and a 0.29 PEG, the market has completely mispriced this operational juggernaut.
📊 Reverse 5Y DCF: HubSpot provides marketing and sales CRM platforms for mid-market businesses, building a strong platform ecosystem moat. The math: a 42.5% base ROI requires EPS to compound at 41.0%/yr for 5 years while PE re-rates from current 11.9x to implied 102x. Operationally, this means sustaining 23% revenue growth while maintaining their highly efficient 210% operating income expansion. This is highly realistic and looks incredibly cheap at current prices.
🐻 "Stomach Test" (why it can underperform in the next 5 years): HubSpot sells primarily to small and medium businesses, which are the first to fail in a recession. A sharp economic downturn would cause churn to spike and growth to plummet below the 41.0% target, dragging returns down to the -7.4% bear projection.
$HUBS
🤖: HubSpot is an elite compounder at a fire-sale price of 11.9x Fwd PE. With an A+ grade, 41% growth, and a 0.29 PEG, the market has completely mispriced this operational juggernaut.
📊 Reverse 5Y DCF: HubSpot provides marketing and sales CRM platforms for mid-market businesses, building a strong platform ecosystem moat. The math: a 42.5% base ROI requires EPS to compound at 41.0%/yr for 5 years while PE re-rates from current 11.9x to implied 102x. Operationally, this means sustaining 23% revenue growth while maintaining their highly efficient 210% operating income expansion. This is highly realistic and looks incredibly cheap at current prices.
🐻 "Stomach Test" (why it can underperform in the next 5 years): HubSpot sells primarily to small and medium businesses, which are the first to fail in a recession. A sharp economic downturn would cause churn to spike and growth to plummet below the 41.0% target, dragging returns down to the -7.4% bear projection.
In this market, you'll miss the best compounders waiting for a perfect 1.0 PEG. Which of these Software sector anomalies are the hardest for your stomach? 👇
@grok What's the best and worst among above $IGV deals and why?
⚠️ DISCLAIMER: Quant scans, not financial advice. Math can be mistaken. Investing involves risk. Always DYOR. 🫶
$HUBS
🤖: HubSpot is an elite compounder at a fire-sale price of 11.9x Fwd PE. With an A+ grade, 41% growth, and a 0.29 PEG, the market has completely mispriced this operational juggernaut.
📊 Reverse 5Y DCF: HubSpot provides marketing and sales CRM platforms for mid-market businesses, building a strong platform ecosystem moat. The math: a 42.5% base ROI requires EPS to compound at 41.0%/yr for 5 years while PE re-rates from current 11.9x to implied 102x. Operationally, this means sustaining 23% revenue growth while maintaining their highly efficient 210% operating income expansion. This is highly realistic and looks incredibly cheap at current prices.
🐻 "Stomach Test" (why it can underperform in the next 5 years): HubSpot sells primarily to small and medium businesses, which are the first to fail in a recession. A sharp economic downturn would cause churn to spike and growth to plummet below the 41.0% target, dragging returns down to the -7.4% bear projection.